Ignite Creation Date:
2025-12-24 @ 11:36 PM
Ignite Modification Date:
2026-03-06 @ 10:09 PM
Study NCT ID:
NCT06839456
Status:
RECRUITING
Last Update Posted:
2025-03-25
First Post:
2025-02-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Sponsor:
Children's Hospital of Philadelphia
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Leukemia | View |
| None | High Risk Acute Lymphoblastic Leukemia | View |
| None | High Risk Acute Myeloid Leukemia | View |
| None | Relapse Leukemia | View |
| None | MDS (Myelodysplastic Syndrome) | View |
| None | Relapsed Non-Hodgkin Lymphoma | View |
| None | Acquired Aplastic Anemia | View |
| None | Inherited BMF Syndrome | View |
| None | Immunodeficiency | View |
| None | Primary Immune Regulatory Disorder | View |
| None | Hemoglobinopathies | View |
| None | Bone Marrow Failure | View |
| None | Inborn Errors of Metabolism | View |
| None | HLH | View |